Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

LOS ANGELES, Oct. 3, 2023 /PRNewswire/ — Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that an equity award has been granted to its new President…

Click here to view original post